Skip to main content

Nouscom secures 67.5 million euros in financing

| News

Nouscom secures 67.5 million euros in financing

14.11.2023

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use the funds to advance the clinical development of its portfolio of neoantigen cancer vaccines, including the evaluation of the ongoing randomized Phase 2 trial.

Nouscom, a Basel-based clinical-stage immuno-oncology company, has raised 67.5 million euros in a Series C financing round. The round was led by Andera PartnersBpifrance (through its InnoBio 2 fund) and M Ventures. Other new and existing investors also participated. As part of this financing, representatives of Andera Partners, Bpifrance and M Ventures were appointed to Nouscom’s Board of Directors, according to a statement.

The biotech company, located in Basel’s Bäumleingasse, is developing standardized and personalized cancer vaccines based on viral vectors targeting neoantigens. According to the statement, the fresh capital will be used to advance Nouscom’s clinical pipeline to the most important clinical endpoints. These include a Phase 2 trial for the treatment of colorectal cancer, an ongoing Phase 1b trial for cancer prophylaxis in Lynch Syndrome carriers, and the completion of a Phase 1b trial for personalized cancer immunotherapy in various indications.

Promising development

If positive, the Phase 2 data for the NOUS-209 vaccine, which simultaneously targets 209 neoantigens, “have the potential to position Nouscom’s neoantigen-based cancer vaccines amongst the most thrilling developments in the field,” commented Nouscom CEO Dr. Marina Udier in the statement. Dr. Sofia Ioannidou, Partner at Andera Partners, believes that the “robustness of the clinical results generated so far positions Nouscom as one of the leading biotech companies in the neoantigen cancer vaccine space”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.